A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets.
Yes, you read that correctly. Hospital elevator buttons showed a 61% prevalence of bacteria colonization, while only 43% of toilet surfaces were colonized in a study covering three teaching hospitals in Toronto, Ontario.
Of course, this has some unfortunate implications for potential cross-contamination in hospitals, although keep in mind that this study only covered three hospitals during a brief period of time. Still, though, this is another data point in a bigger push for hospitals and other businesses to focus on sanitation and help prevent infections from a variety of bacteria including Methicillin-resistant Staphylococcusaureus (also known as MRSA).
Fortunately, new drugs are coming on the market to help fight back against these and other bacteria behind acute bacterial skin and skin structure infections (known as ABSSSI for short, and MRSA can be one of the causes). Durata Therapeutics' (NASDAQ: DRTX ) Dalvance and Cubist Pharmaceuticals' (NASDAQ: CBST.DL ) Sivextro are two newly-approved drugs that can help lead the fight against ABSSSI. Neither is expected to be a blockbuster -- peak sales estimates hover around $400 million each -- but both were brought on the market under the new FDA QIDP (Qualified Infectious Disease Product) designation created to help convince pharma companies to invest more in antibiotics.
In the video below, from Where The Money Is, Motley Fool health care analysts Michael Douglass and David Williamson lay out the opportunity for Durata and Cubist in the ABSSSI space and whether either company has potential as an attractive investment in someone's stock portfolio.
Leaked: This coming blockbuster will make even Cubist and Durata jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.